IBDEI13X ; ; 06-AUG-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,19533,2)
 ;;=^267534
 ;;^UTILITY(U,$J,358.3,19534,0)
 ;;=289.0^^105^1232^55
 ;;^UTILITY(U,$J,358.3,19534,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,19534,1,4,0)
 ;;=4^289.0
 ;;^UTILITY(U,$J,358.3,19534,1,5,0)
 ;;=5^Erthryocytosis, Secondary
 ;;^UTILITY(U,$J,358.3,19534,2)
 ;;=^186856
 ;;^UTILITY(U,$J,358.3,19535,0)
 ;;=238.4^^105^1232^109
 ;;^UTILITY(U,$J,358.3,19535,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,19535,1,4,0)
 ;;=4^238.4
 ;;^UTILITY(U,$J,358.3,19535,1,5,0)
 ;;=5^Polycytheria Rubra Vera
 ;;^UTILITY(U,$J,358.3,19535,2)
 ;;=^96105
 ;;^UTILITY(U,$J,358.3,19536,0)
 ;;=V58.61^^105^1232^126
 ;;^UTILITY(U,$J,358.3,19536,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,19536,1,4,0)
 ;;=4^V58.61
 ;;^UTILITY(U,$J,358.3,19536,1,5,0)
 ;;=5^Warfarin/Coumadin Use
 ;;^UTILITY(U,$J,358.3,19536,2)
 ;;=Warfarin/Coumadin Use^303459
 ;;^UTILITY(U,$J,358.3,19537,0)
 ;;=282.49^^105^1232^117
 ;;^UTILITY(U,$J,358.3,19537,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,19537,1,4,0)
 ;;=4^282.49
 ;;^UTILITY(U,$J,358.3,19537,1,5,0)
 ;;=5^Thalassemia NEC
 ;;^UTILITY(U,$J,358.3,19537,2)
 ;;=^329910
 ;;^UTILITY(U,$J,358.3,19538,0)
 ;;=289.89^^105^1232^15
 ;;^UTILITY(U,$J,358.3,19538,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,19538,1,4,0)
 ;;=4^289.89
 ;;^UTILITY(U,$J,358.3,19538,1,5,0)
 ;;=5^Blood Diseases NEC
 ;;^UTILITY(U,$J,358.3,19538,2)
 ;;=^329887
 ;;^UTILITY(U,$J,358.3,19539,0)
 ;;=238.79^^105^1232^88
 ;;^UTILITY(U,$J,358.3,19539,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,19539,1,4,0)
 ;;=4^238.79
 ;;^UTILITY(U,$J,358.3,19539,1,5,0)
 ;;=5^Lymph/Hematopoietic Tissue NEC
 ;;^UTILITY(U,$J,358.3,19539,2)
 ;;=^334033
 ;;^UTILITY(U,$J,358.3,19540,0)
 ;;=287.30^^105^1232^110
 ;;^UTILITY(U,$J,358.3,19540,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,19540,1,4,0)
 ;;=4^287.30
 ;;^UTILITY(U,$J,358.3,19540,1,5,0)
 ;;=5^Primary Thrombocytopenia
 ;;^UTILITY(U,$J,358.3,19540,2)
 ;;=^332841
 ;;^UTILITY(U,$J,358.3,19541,0)
 ;;=288.09^^105^1232^8
 ;;^UTILITY(U,$J,358.3,19541,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,19541,1,4,0)
 ;;=4^288.09
 ;;^UTILITY(U,$J,358.3,19541,1,5,0)
 ;;=5^Agranulocytosis
 ;;^UTILITY(U,$J,358.3,19541,2)
 ;;=^334042
 ;;^UTILITY(U,$J,358.3,19542,0)
 ;;=V10.21^^105^1232^61
 ;;^UTILITY(U,$J,358.3,19542,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,19542,1,4,0)
 ;;=4^V10.21
 ;;^UTILITY(U,$J,358.3,19542,1,5,0)
 ;;=5^H/O Laryngeal Cancer
 ;;^UTILITY(U,$J,358.3,19542,2)
 ;;=^295214
 ;;^UTILITY(U,$J,358.3,19543,0)
 ;;=284.2^^105^1232^106
 ;;^UTILITY(U,$J,358.3,19543,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,19543,1,4,0)
 ;;=4^284.2
 ;;^UTILITY(U,$J,358.3,19543,1,5,0)
 ;;=5^Myelophthisic Anemia
 ;;^UTILITY(U,$J,358.3,19543,2)
 ;;=^334037
 ;;^UTILITY(U,$J,358.3,19544,0)
 ;;=202.40^^105^1232^76
 ;;^UTILITY(U,$J,358.3,19544,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,19544,1,4,0)
 ;;=4^202.40
 ;;^UTILITY(U,$J,358.3,19544,1,5,0)
 ;;=5^Hairy Cell Leukemia,Unspecified site
 ;;^UTILITY(U,$J,358.3,19544,2)
 ;;=^69587
 ;;^UTILITY(U,$J,358.3,19545,0)
 ;;=287.49^^105^1232^118
 ;;^UTILITY(U,$J,358.3,19545,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,19545,1,4,0)
 ;;=4^287.49
 ;;^UTILITY(U,$J,358.3,19545,1,5,0)
 ;;=5^Thrombocytopenia,Drug Induced
 ;;^UTILITY(U,$J,358.3,19545,2)
 ;;=^339610
 ;;^UTILITY(U,$J,358.3,19546,0)
 ;;=180.9^^105^1232^29
 ;;^UTILITY(U,$J,358.3,19546,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,19546,1,4,0)
 ;;=4^180.9
 ;;^UTILITY(U,$J,358.3,19546,1,5,0)
 ;;=5^Ca Cervix
 ;;^UTILITY(U,$J,358.3,19546,2)
 ;;=^267214
 ;;^UTILITY(U,$J,358.3,19547,0)
 ;;=203.02^^105^1232^104
 ;;
 ;;$END ROU IBDEI13X
